## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Baclofen oral suspension (Fleqsuvy)

## Notes:

• Quantity Limits: Yes

Initiation (new start) criteria, criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously, and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary baclofen oral suspension (Fleqsuvy) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a diagnosis of multiple sclerosis, OR history of spinal cord injury, OR history of spinal cord disease
- Patient has failed an adequate trial of baclofen tablets OR is not able to swallow tablets
- Patient has failed an adequate trial of oral baclofen solution (Ozobax or generic)

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary baclofen oral suspension (Fleqsuvy) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a diagnosis of multiple sclerosis, OR history of spinal cord injury, OR history of spinal cord disease
- Patient has failed an adequate trial of baclofen tablets OR is not able to swallow tablets
- Patient has failed an adequate trial of oral baclofen solution (Ozobax or generic)

kp.org

Revised: 05/12/22 Effective: 07/21/22



